Diabetes

Novo Nordisk NVO recently launched Awiqli (insulin icodec-abae) in the United States, introducing the first once-weekly basal insulin for…

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be…

Danish pharmaceutical company ‘Novo Nordisk’ has launched a once-weekly insulin injection in the US market. EPA/MARTIN DIVISEK/Yonhap News…

Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing frequency of these weekly…

Q: What is Novo Nordisk’s current positioning in the Mexican market, and what are the primary factors driving…

Novo Nordisk is taking its legal dispute with Eli Lilly to the next level by seeking a preliminary…

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a…

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a…

Novo Nordisk South Africa is set to launch the country’s first and only authorised copy of semaglutide later…

Novo Nordisk has secured European Commission approval for its once-daily Wegovy pill, giving the Danish drugmaker a major…

Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, where diabetes…

Representational Image (IANS) New Delhi: Danish pharma major Novo Nordisk on Thursday launched in India its once-weekly basal…

Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?